Publication date: Dec 14, 2025
The success of mRNA vaccines during the COVID-19 pandemic has revealed a revolutionary platform for addressing neglected parasite zoonosis, which represent a continual and significant threat to world health, especially in resource-constrained settings. The current review consolidates recent progress in the development of mRNA-based treatments, vaccines, and diagnostic ways for these pathogens. We elucidate how customized delivery platforms, particularly lipid nanoparticles, augment the stability and immunogenicity of parasite-derived mRNA cargo by safeguarding it from degradation and promoting uptake by antigen-presenting cells. Our findings suggest that mRNA technology provides a particularly adaptable strategy to targeting complicated parasite life cycles and efficiently modulating host immune responses. However, important challenges, such as cold-chain logistics, scalability, clinical trial design for diverse populations, and managing public opinion, must be solved beforehand. Future initiatives must priorities the creation of thermostable formulations and effective community participation strategies. Finally, this review emphasizes that mRNA-based interventions represent a promising, albeit challenging, frontier in the fight against parasitic diseases, urging a collaborative cross-disciplinary effort to translate this potential into tangible health breakthroughs for the world’s most vulnerable populations.
| Concepts | Keywords |
|---|---|
| Cold | Helminths |
| Host | mRNA |
| Nanobiotechnology | Protozoan |
| Vaccines | Zoonosis |
| Zoonosis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | parasitic infections |
| drug | DRUGBANK | Spinosad |
| disease | MESH | COVID-19 pandemic |